We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Briefs AdComm on High Risk, Limited Benefit of Spectrum’s Pozenveo
FDA Briefs AdComm on High Risk, Limited Benefit of Spectrum’s Pozenveo
In briefing documents, the FDA expressed four major concerns about Pozenveo (poziotinib), Spectrum Pharmaceutical’s experimental lung and breast cancer drug, ahead of today’s meeting of the FDA’s Oncologic Drugs Advisory Committee.